Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis
Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis
复制标题
DOI：
10.1016/j.clim.2011.09.006
复制
发表时间：
2011-12-01
影响因子：
8.6
通讯作者：
Comabella, M.
中科院分区：
文献类型：
--
作者：
Martinez-Rodriguez, J. E.;Lopez-Botet, M.;Comabella, M.
CD 56（亮）NK细胞可能在免疫调节中起作用，在接受免疫调节疗法（如达克珠单抗和干扰素-β（IFN β））治疗的多发性硬化症（MS）患者中扩增。然而，这种NK细胞亚群是否直接参与治疗效果尚不清楚。由于NK细胞和CD 8 + T淋巴细胞亚群的NK受体（NKR）表达与MS临床病程相关，我们根据临床反应探讨了IFN β治疗的MS患者中CD 56（亮）NK细胞和NKR是否不同。IFN β与较低的LILRB 1+和KIR+NK细胞以及较高的NKG 2A +NK细胞比例相关，这是一种主要见于应答者的免疫表型模式。IFN β治疗后，CD 56（亮）NK细胞扩增与阳性临床应答显著相关。我们的研究结果表明，IFN β可能会促进应答者NK细胞免疫表型的变化，对应于该淋巴细胞系早期成熟阶段的特征。(C)2011 Elsevier Inc. All rights reserved.
CD56(bright) NK cells, which may play a rote in immunoregulation, are expanded in multiple sclerosis (MS) patients treated with immunomodulatory therapies such as daclizumab and interferon-beta (IFN beta). Yet, whether this NK cell subset is directly involved in the therapeutic effect is unknown. As NK receptor (NKR) expression by subsets of NK cells and CD8+ T lymphocytes is related to MS clinical course, we addressed whether CD56(bright) NK cells and NKR in IFN beta-treated MS patients differ according to the clinical response. IFN beta was associated to lower LILRB1+ and KIR+NK cells, and higher NKG2A+NK cell proportions, an immunophenotypic pattern mainly found in responders. After IFN beta treatment, a CD56(bright) NK cell expansion was significantly related to a positive clinical response. Our results reveal that IFN beta may promote in responders changes in the NK cell immunophenotype, corresponding to the profile found at early maturation stages of this lymphocyte lineage. (C) 2011 Elsevier Inc. All rights reserved.